Alexander U. Ernst

ORCID: 0000-0001-6209-8486
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pancreatic function and diabetes
  • Diabetes Management and Research
  • Tissue Engineering and Regenerative Medicine
  • Diabetes and associated disorders
  • Electrospun Nanofibers in Biomedical Applications
  • 3D Printing in Biomedical Research
  • Electrohydrodynamics and Fluid Dynamics
  • Cerebrovascular and Carotid Artery Diseases
  • Aortic aneurysm repair treatments
  • Adenosine and Purinergic Signaling
  • Cannabis and Cannabinoid Research

Cornell University
2018-2023

Ithaca College
2018-2019

Transplantation of stem cell-derived β (SC-β) cells represents a promising therapy for type 1 diabetes (T1D). However, the delivery, maintenance, and retrieval these remain challenge. Here, we report design safe functional device composed highly porous, durable nanofibrous skin an immunoprotective hydrogel core. The consists electrospun medical-grade thermoplastic silicone-polycarbonate-urethane is soft but tough (~15 megapascal at rupture strain >2). Tuning nanofiber size to less than ~500...

10.1126/scitranslmed.abb4601 article EN Science Translational Medicine 2021-06-02

Abstract Inadequate oxygenation is a major challenge in cell encapsulation, therapy which holds potential to treat many diseases including type I diabetes. In such systems, cellular oxygen (O 2 ) delivery limited slow passive diffusion from transplantation sites through the poorly O -soluble encapsulating matrix, usually hydrogel. This constrains maximum permitted distance between encapsulated cells and host site within few hundred micrometers ensure function. Inspired by natural gas-phase...

10.1038/s41467-021-26126-w article EN cc-by Nature Communications 2021-10-06

A cell encapsulation system generates oxygen from carbon dioxide for self-oxygenation.

10.1126/sciadv.abd5835 article EN cc-by-nc Science Advances 2021-05-14

Abstract Islet encapsulation and transplantation promises to improve upon current treatments for type 1 diabetes mellitus, though several limitations remain. Macroscale devices have been designed in vivo retrieval, but traditional geometries do not support clinically adequate mass transfer of nutrients insulin from the encapsulated tissue. Microcapsule technologies improved properties, their clinical translation remains challenging as complete retrieval is difficult, should graft become a...

10.1002/adhm.201900423 article EN Advanced Healthcare Materials 2019-05-21

Abstract Encapsulation and transplantation of insulin‐producing cells offer a promising curative treatment for type 1 diabetes (T1D) without immunosuppression. However, biomaterials used to encapsulate often elicit foreign body responses, leading cellular overgrowth deposition fibrotic tissue, which in turn diminishes mass transfer from transplanted cells. Meanwhile, the encapsulation device must be safe, scalable, ideally retrievable meet clinical requirements. Here, durable safe...

10.1002/smll.202104899 article EN Small 2021-12-13

Review of emerging advances and persisting challenges in the engineering translation islet encapsulation technologies.

10.1039/c8tb02020e article EN Journal of Materials Chemistry B 2018-01-01

Abstract The delivery of encapsulated islets or stem cell-derived insulin-producing cells (i.e., bioartificial pancreas devices) may achieve a functional cure for type 1 diabetes, but their efficacy is limited by mass transport constraints. Modeling such constraints thus desirable, previous efforts invoke simplifications which limit the utility insights. Herein, we present computational platform investigating therapeutic capacity generic and user-programmable devices, accounts highly...

10.1038/s41467-022-33760-5 article EN cc-by Nature Communications 2022-10-13

Cell replacement therapy is emerging as a promising treatment platform for many endocrine disorders and hormone deficiency diseases. The survival of cells within delivery devices is, however, often limited due to low oxygen levels in common transplantation sites. Additionally, replacing implanted at the end graft lifetime unfeasible and, where possible, generally requires invasive surgical procedures. Here, design testing modular transcutaneous biphasic (BP) cell device that provides...

10.1002/adma.201905135 article EN Advanced Materials 2019-11-11

Implanted cell-containing grafts require a robust and functional vasculature to supply oxygen nutrients, as well clear metabolic waste products. However, it remains challenging fabricate tunable, vascular-promoting scaffolds without incorporating additional biologics. Here, biphasic gel consisting of highly porous aerogel degradable fibrin hydrogel for inducing vascularization is presented. The (>90%) stable assembled from short microfibers by being dispersed in an aqueous solution that can...

10.1002/adhm.202200922 article EN publisher-specific-oa Advanced Healthcare Materials 2022-07-27
Coming Soon ...